Research graph
References from Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Local targets link to admitted publications; unresolved targets remain external evidence.
Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal
10.1002/1097-0142(19830515)51:10<1826::aid-cncr2820511012>3.0.co;2-l · 1983 · External reference
Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research
10.1016/s0140-6736(96)03409-5 · 1996 · External reference
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial
10.1001/jama.299.16.1914 · 2008 · External reference
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin
10.1200/jco.2012.43.8085 · 2012 · External reference
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial
10.1016/s1470-2045(13)70086-x · 2013 · External reference
Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy
10.1016/j.ijrobp.2006.11.038 · 2007 · External reference
Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience
10.1200/jco.2007.12.0170 · 2007 · External reference
Impact of overall treatment time on survival and local control in patients with anal cancer: A pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11
10.1200/jco.2010.29.1351 · 2010 · External reference
Intensity-modulated radiation therapy for anal malignancies: A preliminary toxicity and disease outcomes analysis
10.1016/j.ijrobp.2009.09.046 · 2010 · External reference
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal
10.1002/cncr.25901 · 2011 · External reference
Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer
10.1016/j.ijrobp.2014.06.061 · 2014 · External reference
Intensity-modulated radiation therapy for anal cancer: Results from a multi-institutional retrospective cohort study
10.1097/coc.0000000000000009 · 2016 · External reference
Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3-year outcomes at two Sydney institutions
10.1016/j.clon.2015.08.006 · 2015 · External reference
Locally advanced (T3-T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy
2016 · External reference
Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas
10.1016/j.ijrobp.2008.08.070 · 2009 · External reference
RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal
10.1016/j.ijrobp.2012.09.023 · 2013 · External reference
Unresolved reference
External reference
Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients
10.1016/j.ijrobp.2008.10.046 · 2009 · External reference
